American Surgical Association (ASA)
Annual Meeting
Members Only
About / History

Search ASA
130th Annual Meeting Abstracts

Surgical Quality And Nodal Ultrastaging Is Associated With Long-term Disease-free Survival In Early Colorectal Cancer: An Analysis Of Two International Multicenter Prospective Trials
Anton Bilchik1, *Avi Nissan2, *Zev Wainberg1, *Perry Shen3, *Martin McCarter4, *Mladjan Protic5, *Robin Howard6, *David Elashoff1, *George Peoples6, *Alexander Stojadinovic6
1University of California Los Angeles, Los Angeles, CA;2Hadassah University, Jerusalem, Israel3Wake Forest University, Winston Salem, NC;4University of Colorado, Denver, CO;5University of Novi Sad, Novi Sad, Serbia6Uniformed Services University of the Health Sciences, Washington, DC

Objective: The National Quality Forum has endorsed a 12 lymph node (LN) minimum as a surrogate measure of quality in colorectal cancer (CRC). The prognostic value of ultrastaging hematoxylin and eosin (H&E) negative LN’s (N0) using cytokeratin immunohistochemistry (CK-IHC) is unknown. We hypothesized that both surgical quality and focused pathology analysis improves survival.
Methods: Between 2001 and 2007, 253 evaluable patients with resectable CRC were enrolled. Multiple sectioning and CK-IHC was performed on N0 LN’s (stage II). The primary end-point was four-year disease free survival (DFS).
Results: There were 177 (70%) patients with N0 and 76 (30%) with N1 disease. Using ultrastaging in N0 patients, 36 (20%) were found to have micrometastases (MM). At a mean follow up of 3.4 years (± 1.6), 39 (15%) have recurred. The recurrence rate was only 3.7% in patients > 12 LN’s, negative by H&E and IHC, compared to 18.8% with <12 LN’s (P*=0.0032).
4 yr DFS based on AJCC Stage and LN number

* log rank test
Summary: This represents the first prospective report demonstrating that both surgical quality and nodal ultrastaging impacts survival in Stage II CRC. Patients with Stage II CRC with >12 LN’s negative for MM (N0i-) are likely cured by surgery alone. Both surgical and pathological quality measures are imperative in early CRC in order to improve patient selection for adjuvant chemotherapy.


© Copyright 2019. Privacy Policy
American Surgical Association
500 Cummings Center, Suite 4400, Beverly, MA 01915
(978) 927-8330 | FAX (978) 524-0498
Email ASA
11:40:19 AM
Saturday, August 17, 2019